PharmaShots

APRIL 28, 2023

Difficile Infection Date: Apr 27, 2023 | Tags: Seres Therapeutics, Nestlé Health Science, Vowst, C.

FDA 56

FDA 56

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines.

Immunization 52

Immunization Vaccines 52

European Pharmaceutical Review

MAY 11, 2023

Novartis shared long-term data for its SMA gene therapy in March 2023, which indicated significant long-term motor-milestone achievements in spinal muscular atrophy (SMA). 3 The one-time gene therapy received final draft guidance from the National Institute for Health and Care Excellence (NICE) on 16 March 2023.

FDA 71

FDA 71

pharmaphorum

AUGUST 18, 2022

bluebird bio’s Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood transfusions. million for chelation therapy to remove excess iron from the body. bluebird has opted to launch it at a cost of $2.8

FDA 52

FDA Insurance 52

Viseven

SEPTEMBER 14, 2023

Climate change is another factor, potentially disrupting supplies and contributing to hefty price tags. In this article, the Viseven team aims to explain how pharma procurement works and to cover effective strategies to transform this process at any level, from local campaigns to national health programs.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Pharmacy Procurement 52